131 related articles for article (PubMed ID: 24268019)
1. Cost drivers of prescription opioid abuse in commercial and Medicare populations.
Pasquale MK; Joshi AV; Dufour R; Schaaf D; Mardekian J; Andrews GA; Patel NC
Pain Pract; 2014 Mar; 14(3):E116-25. PubMed ID: 24268019
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.
Dufour R; Joshi AV; Pasquale MK; Schaaf D; Mardekian J; Andrews GA; Patel NC
Pain Pract; 2014 Mar; 14(3):E106-15. PubMed ID: 24289539
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and cost of diagnosed opioid abuse in a privately insured population in the United States.
Roland CL; Joshi AV; Mardekian J; Walden SC; Harnett J
J Opioid Manag; 2013; 9(3):161-75. PubMed ID: 23771567
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning.
Roland CL; Ye X; Stevens V; Oderda GM
J Manag Care Spec Pharm; 2019 Jan; 25(1):18-27. PubMed ID: 30589633
[TBL] [Abstract][Full Text] [Related]
5. Differences in healthcare utilization and associated costs between patients prescribed vs. nonprescribed opioids during an inpatient or emergency department visit.
Xie L; Joshi AV; Schaaf D; Mardekian J; Harnett J; Shah ND; Baser O
Pain Pract; 2014 Jun; 14(5):446-56. PubMed ID: 23809064
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
Shei A; Rice JB; Kirson NY; Bodnar K; Enloe CJ; Birnbaum HG; Holly P; Ben-Joseph R
J Manag Care Spec Pharm; 2015 Oct; 21(10):902-12. PubMed ID: 26402390
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration.
Baser O; Xie L; Mardekian J; Schaaf D; Wang L; Joshi AV
Pain Pract; 2014 Jun; 14(5):437-45. PubMed ID: 23809020
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs and nonadherence among chronic opioid users.
Leider HL; Dhaliwal J; Davis EJ; Kulakodlu M; Buikema AR
Am J Manag Care; 2011 Jan; 17(1):32-40. PubMed ID: 21348566
[TBL] [Abstract][Full Text] [Related]
9. The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.
Kirson NY; Shei A; Rice JB; Enloe CJ; Bodnar K; Birnbaum HG; Holly P; Ben-Joseph R
Pain Med; 2015 Jul; 16(7):1325-32. PubMed ID: 25929289
[TBL] [Abstract][Full Text] [Related]
10. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events.
Chandwani HS; Strassels SA; Rascati KL; Lawson KA; Wilson JP
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):206-13. PubMed ID: 23879214
[TBL] [Abstract][Full Text] [Related]
11. The Economic Burden of Opioid Abuse: Updated Findings.
Kirson NY; Scarpati LM; Enloe CJ; Dincer AP; Birnbaum HG; Mayne TJ
J Manag Care Spec Pharm; 2017 Apr; 23(4):427-445. PubMed ID: 28345440
[TBL] [Abstract][Full Text] [Related]
12. Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Birnbaum HG; White AG; Schiller M; Waldman T; Cleveland JM; Roland CL
Pain Med; 2011 Apr; 12(4):657-67. PubMed ID: 21392250
[TBL] [Abstract][Full Text] [Related]
13. Natural Language Processing-Identified Problem Opioid Use and Its Associated Health Care Costs.
Masters ET; Ramaprasan A; Mardekian J; Palmer RE; Gross DE; Cronkite D; Von Korff M; Carrell DS
J Pain Palliat Care Pharmacother; 2018; 32(2-3):106-115. PubMed ID: 30702378
[TBL] [Abstract][Full Text] [Related]
14. Costs of opioid abuse and misuse determined from a Medicaid database.
McAdam-Marx C; Roland CL; Cleveland J; Oderda GM
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):5-18. PubMed ID: 20345194
[TBL] [Abstract][Full Text] [Related]
15. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
16. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
17. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
18. Drivers of excess costs of opioid abuse among a commercially insured population.
Scarpati LM; Kirson NY; Zichlin ML; Jia ZB; Birnbaum HG; Howard JC
Am J Manag Care; 2017 May; 23(5):276-282. PubMed ID: 28738684
[TBL] [Abstract][Full Text] [Related]
19. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.
Birnbaum HG; White AG; Reynolds JL; Greenberg PE; Zhang M; Vallow S; Schein JR; Katz NP
Clin J Pain; 2006 Oct; 22(8):667-76. PubMed ID: 16988561
[TBL] [Abstract][Full Text] [Related]
20. Opioid analgesic-treated chronic pain patients at risk for problematic use.
Tkacz J; Pesa J; Vo L; Kardel PG; Un H; Volpicelli JR; Ruetsch C
Am J Manag Care; 2013 Nov; 19(11):871-80. PubMed ID: 24511985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
